<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340048</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1018</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091018</ELocationID><Abstract><AbstractText>This is a retrospective observational study including all COVID-19 patients admitted at our Institute throughout three successive pandemic waves, from January 2021 to June 2023. The main in-hospital outcomes (clinical progression [CP], defined as admission to Intensive Care Unit [ICU]/death, and death within 28 days) were compared among participants unvaccinated (NV), fully vaccinated (FV), with one (FV&amp;B1) and two (FV&amp;B2) booster doses. Vaccinated participants were stratified into recently and waned FV/FV&amp;B1/FV&amp;B2, depending on the time elapsed from last dose (≤ and &gt;120 days, respectively). There were 4488 participants: 2224 NV, 674 FV, 1207 FV&amp;B1, and 383 FV&amp;B2. Within 28 days, there were 604 ICU admissions, 396 deaths, and 737 CP. After adjusting for the main confounders, the risk of both in-hospital outcomes was reduced in vaccinated individuals, especially in those who received the booster dose (approximately by 36% for FV and &gt;50% for FV&amp;B1 and FV&amp;B2 compared to NV). Similarly, after restricting the analysis to vaccinated participants only, we observed a risk reduction of approximately 40% for FV&amp;B1 and 50% for FV&amp;B2, compared to FV, regardless of the distance since the last dose. Our data confirm the vaccine's effectiveness in preventing severe COVID-19 and support the efforts to increase the uptake of booster doses, mainly among older and frailer individuals, still at a greater risk of clinical progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mondi</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrorosa</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-1944-662X</Identifier><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarra</LastName><ForeName>Assunta</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3662-4312</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimaglia</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinnetti</LastName><ForeName>Carmela</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzotta</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0240-7504</Identifier><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agresta</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corpolongo</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6235-3934</Identifier><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zolezzi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Moghazi</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loiacono</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocci</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-6100-8442</Identifier><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matusali</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2948-4243</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Annunzio</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallì</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7489-5271</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vairo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8182-5896</Identifier><AffiliationInfo><Affiliation>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antinori</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2121-4684</Identifier><AffiliationInfo><Affiliation>Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Italian Ministry of Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine booster shot</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">critical illness</Keyword><Keyword MajorTopicYN="N">death</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword></KeywordList><CoiStatement>A.M. received travel fees from ViiV Healthcare. V.M. received personal payments/honoraria from AstraZeneca, Pfizer, and GSK, and support for attending meetings and/or travel by AstraZeneca. E.G. received personal payments from Gilead Sciences and institutional grants from Gilead Sciences and Mylan. A.A. (Andrea Antinori) has served as a paid consultant to AstraZeneca, Bavarian Nordic, Gilead Sciences, GSK, Janssen-Cilag, Merck, Moderna, Pfizer, and ViiV Healthcare and received research funding through the National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS from AstraZeneca, Gilead Sciences, and ViiV Healthcare. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340048</ArticleId><ArticleId IdType="pmc">PMC11435849</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091018</ArticleId><ArticleId IdType="pii">vaccines12091018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 Dashboard.  [(accessed on 10 July 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>COVID-19 National Vaccination Strategic Plan.  [(accessed on 10 July 2024)].  Available online:  https://www.epicentro.iss.it/vaccini/covid-19-piano-vaccinazione.</Citation></Reference><Reference><Citation>Italian Ministry of Health  Circolare Ministeriale del.  [(accessed on 10 July 2024)];2021 September 14; Available online:  https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&amp;codLeg=82776&amp;parte=1%20&amp;serie=null.</Citation></Reference><Reference><Citation>Italian Ministry of Health  Circolare Ministeriale del.  [(accessed on 10 July 2024)];2022 February 20; Available online:  https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2022&amp;codLeg=85813&amp;parte=1%20&amp;serie=null.</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. Corrected in Lancet 2021, 397, 98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., Brooks N., Smaja M., Mircus G., Pan K., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet. 2021;397:1819–1829. doi: 10.1016/S0140-6736(21)00947-8. Corrected in Lancet 2021, 398, 212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., Dagan N., Ben-Shlomo Y., Kepten E., Waxman J., Ohana R., Hernán M.A., Lipsitch M., Kohane I., Netzer D., et al. Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting. N. Engl. J. Med. 2021;385:1078–1090. doi: 10.1056/NEJMoa2110475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanatidou E., Gkiouliava A., Pella E., Serafidi M., Tsilingiris D., Vallianou N.G., Karampela Ι., Dalamaga M. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabol. Open. 2022;14:100180. doi: 10.1016/j.metop.2022.100180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2022.100180</ArticleId><ArticleId IdType="pmc">PMC8928742</ArticleId><ArticleId IdType="pubmed">35313532</ArticleId></ArticleIdList></Reference><Reference><Citation>Solante R., Alvarez-Moreno C., Burhan E., Chariyalertsak S., Chiu N.C., Chuenkitmongkol S., Dung D.V., Hwang K.P., Ortiz Ibarra J., Kiertiburanakul S., et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert. Rev. Vaccines. 2023;22:1–16. doi: 10.1080/14760584.2023.2143347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2143347</ArticleId><ArticleId IdType="pubmed">36330971</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U., Bedston S., McCowan C., Oke J., Patterson L., Robertson C., Akbari A., Azcoaga-Lorenzo A., Bradley D.T., Fagbamigbe A.F., et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: Pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wale. Lancet. 2022;400:1305–1320. doi: 10.1016/S0140-6736(22)01656-7. Corrected in Lancet 2024, 403, 1140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01656-7</ArticleId><ArticleId IdType="pmc">PMC9560746</ArticleId><ArticleId IdType="pubmed">36244382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Moustsen-Helms I.R., Rasmussen M., Søborg B., Ullum H., Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: A national cohort study. Lancet Infect. Dis. 2024;24:e73–e74. doi: 10.1016/S1473-3099(23)00746-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00746-6</ArticleId><ArticleId IdType="pubmed">38190834</ArticleId></ArticleIdList></Reference><Reference><Citation>van Werkhoven C.H., Valk A.W., Smagge B., de Melker H.E., Knol M.J., Hahné S.J., van den Hof S., de Gier B. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, The Netherlands, 9 October to 5 December 2023. Eurosurveillance. 2024;29:2300703. doi: 10.2807/1560-7917.ES.2024.29.1.2300703.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.1.2300703</ArticleId><ArticleId IdType="pmc">PMC10905658</ArticleId><ArticleId IdType="pubmed">38179623</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCuir J., Payne A.B., Self W.H., Rowley E.A.K., Dascomb K., DeSilva M.B., Irving S.A., Grannis S.J., Ong T.C., Klein N.P., et al. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years—VISION and IVY Networks, September 2023-January 2024. MMWR Morb. Mortal. Wkly. Rep. 2024;73:180–188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10907041</ArticleId><ArticleId IdType="pubmed">38421945</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxembourg M. Interim Analysis of COVID-19 Vaccine Effectiveness Against Hospitalisation Due to COVID-19 and Death Using Electronic Health Records in Eight European Countries: First Update. ECDC; Stockholm, UK: 2024.</Citation></Reference><Reference><Citation>Yeh Y.P., Lin T.Y., Yao Y.C., Hsu C.Y., Yen A.M.F., Chen S.L.S., Chen T.H.H. New insights into three trajectories of omicron-related all-cause death reduced by COVID-19 booster vaccination. J. Infect. Public Health. 2024;17:735–740. doi: 10.1016/j.jiph.2024.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2024.03.006</ArticleId><ArticleId IdType="pubmed">38518679</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita V., Syed A.M., Morris M.K., Brazer N., Saldhi P., Garcia-Knight M., Sreekumar B., Khalid M.M., Ciling A., Chen P.Y., et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022;185:1539–1548.e5. doi: 10.1016/j.cell.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC8930394</ArticleId><ArticleId IdType="pubmed">35429436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Self W.H., Adams K., Gaglani M., Ginde A.A., McNeal T., Ghamande S., Douin D.J., Talbot H.K., Casey J.D., et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326:2043–2054. doi: 10.1001/jama.2021.19499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.19499</ArticleId><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>d’Arminio Monforte A., Tavelli A., De Benedittis S., Bai F., Tincati C., Gazzola L., Viganò O., Allegrini M., Mondatore D., Tesoro D., et al. Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. Vaccines. 2022;10:550. doi: 10.3390/vaccines10040550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10040550</ArticleId><ArticleId IdType="pmc">PMC9031136</ArticleId><ArticleId IdType="pubmed">35455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker R., Kristofferson A.B., Salamanca B.V., Seppälä E., Golestani K., Kvåle R., Watle S.V., Buanes E.A. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: A register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin. Microbiol. Infect. 2022;28:871–878. doi: 10.1016/j.cmi.2022.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.033</ArticleId><ArticleId IdType="pmc">PMC8872711</ArticleId><ArticleId IdType="pubmed">35219807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke N., Johnson S., Bahl A. Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis. Lancet Reg. Health Am. 2022;8:100227. doi: 10.1016/j.lana.2022.100227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100227</ArticleId><ArticleId IdType="pmc">PMC8926847</ArticleId><ArticleId IdType="pubmed">35313615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Giardin J.M., Rivilla M., Mesa N., Morales A., Rivas L., Izquierdo A., Escribá A., San Martín J.V., Bernal-Bello D., Madroñal E., et al. Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants. Viruses. 2022;14:2284. doi: 10.3390/v14102284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102284</ArticleId><ArticleId IdType="pmc">PMC9611498</ArticleId><ArticleId IdType="pubmed">36298839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang Y., Huang C., Yang H., Jiang C., Yu X., Zhao R., Hong J., Zhang Y., Wang Y., et al. Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak. Hum. Vaccin. Immunother. 2024;20:2361500. doi: 10.1080/21645515.2024.2361500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2361500</ArticleId><ArticleId IdType="pmc">PMC11195489</ArticleId><ArticleId IdType="pubmed">38904423</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholinataj Jelodar M., Mirzaei S., Saghafi F., Rafieian S., Rezaei S., Saatchi A., Dehghani Avare Z., Dehghan Niri M. Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients. BMC Infect. Dis. 2024;24:254. doi: 10.1186/s12879-024-09139-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09139-w</ArticleId><ArticleId IdType="pmc">PMC10893624</ArticleId><ArticleId IdType="pubmed">38395855</ArticleId></ArticleIdList></Reference><Reference><Citation>Italian National Institute of Health (Istituto Superiore di Sanità, ISS)  Monitoraggio Delle Varianti del Virus SARS-CoV-2 di Interesse in Sanità Pubblica in Italia.  [(accessed on 10 July 2024)].  Available online:  https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-rapporti-periodici.</Citation></Reference><Reference><Citation>Mondi A., Mastrorosa I., Piselli P., Cimaglia C., Matusali G., Carletti F., Giannico G., Milozzi E., Biliotti E., Di Bari S., et al. Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes. J. Med. Virol. 2023;95:e28831. doi: 10.1002/jmv.28831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28831</ArticleId><ArticleId IdType="pubmed">37246793</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittinghoff E., Glidden D.V., Shiboski S.C., McCulloch C.E. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. Springer Publishing Co.; New York, NY, USA: 2005.</Citation></Reference><Reference><Citation>Chatterjee S., Simonoff J.S. Handbook of Regression Analysis. John Wiley &amp; Sons; Hoboken, NJ, USA: 2013.</Citation></Reference><Reference><Citation>Struttura Commissariale per l’Emergenza COVID-19  Open Data on COVID-19 Vaccination in Italy.  [(accessed on 10 July 2024)].  Available online:  https://github.com/italia/covid19-opendata-vaccini.</Citation></Reference><Reference><Citation>Goel R.R., Painter M.M., Lundgreen K.A., Apostolidis S.A., Baxter A.E., Giles J.R., Mathew D., Pattekar A., Reynaldi A., Khoury D.S., et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022;185:1875–1887.e8. doi: 10.1016/j.cell.2022.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC8989683</ArticleId><ArticleId IdType="pubmed">35523182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Jia Z., Bao L., Wang L., Cao L., Chi H., Hu Y., Li Q., Zhou Y., Jiang Y., et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603:919–925. doi: 10.1038/s41586-022-04466-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04466-x</ArticleId><ArticleId IdType="pmc">PMC8967717</ArticleId><ArticleId IdType="pubmed">35090164</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F., Wang Z., Cho A., Gaebler C., Ben Tanfous T., DaSilva J., Bednarski E., Ramos V., Zong S., Johnson B., et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607:128–134. doi: 10.1038/s41586-022-04778-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04778-y</ArticleId><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor C.A., Patel K., Patton M.E., Reingold A., Kawasaki B., Meek J., Openo K., Ryan P.A., Falkowski A., Bye E., et al. COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥ 65 Years—COVID-NET, 13 States, January-August 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1089–1094. doi: 10.15585/mmwr.mm7240a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7240a3</ArticleId><ArticleId IdType="pmc">PMC10564325</ArticleId><ArticleId IdType="pubmed">37796744</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: Systematic review and meta-analysis. Int. Urol. Nephrol. 2023;55:791–802. doi: 10.1007/s11255-023-03471-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-023-03471-x</ArticleId><ArticleId IdType="pmc">PMC9890430</ArticleId><ArticleId IdType="pubmed">36723829</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., Dube S., Lu Y., Yates M., Arnetorp S., Barnes E., Bell S., Carty L., Evans K., Graham S., et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: Insights from the observational population-based INFORM study. Lancet Reg. Health Eur. 2023;35:100747. doi: 10.1016/j.lanepe.2023.100747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100747</ArticleId><ArticleId IdType="pmc">PMC10730312</ArticleId><ArticleId IdType="pubmed">38115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P., Parczewski M., Serwin K., Marchetti G., Bai F., Jensen B.E.O., Pereira J.P., Drobniewski F., Reschreiter H., Naumovas D., et al. In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: A multinational cohort study in the EuCARE project. Lancet Reg. Health Eur. 2024;38:100855. doi: 10.1016/j.lanepe.2024.100855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2024.100855</ArticleId><ArticleId IdType="pmc">PMC10928271</ArticleId><ArticleId IdType="pubmed">38476753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., Wu Q., Pan H., Li M., Yang J., Wang L., Wu Z., Jiang D., Deng X., Chu K., et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 2022;22:483–495. doi: 10.1016/S1473-3099(21)00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayyalasomayajula S., Dhawan A., Karattuthodi M.S., Thorakkattil S.A., Abdulsalim S., Elnaem M.H., Sridhar S., Unnikrishnan M.K. A Systematic Review on Sociodemographic, Financial and Psychological Factors Associated with COVID-19 Vaccine Booster Hesitancy among Adult Population. Vaccines. 2023;11:623. doi: 10.3390/vaccines11030623.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030623</ArticleId><ArticleId IdType="pmc">PMC10051942</ArticleId><ArticleId IdType="pubmed">36992207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>